www.gjhsr.org

Global Journal of Health Science and Research

Article in Press

Review Article

Advancements and challenges in pediatric pharmacotherapy: A comprehensive review

Tahir Bashir Khan[1]

[1]Department of Pharmacy Practice, Adesh University, Buchu Kalan, Bathinda, India.

***Corresponding author:**
Tahir Bashir Khan,
Department of Pharmacy Practice, Adesh University, Buchu Kalan, Bathinda, India.

tahirbasher532@gmail.com

Received: 06 October 2024
Accepted: 06 January 2025
EPub Ahead of Print: 01 March 2025
Published:

DOI
10.25259/GJHSR_50_2024

Quick Response Code:

ABSTRACT

Pediatric pharmacotherapy requires tailored approaches due to age-related physiological differences that significantly affect drug pharmacokinetics and pharmacodynamics. This review explores key challenges in pediatric drug therapy, including formulation difficulties, the impact of obesity on dosing, and the scarcity of evidence-based dosage guidelines. The review also discusses the Society of Critical Care Medicine's guidelines for managing pain, sedation, and delirium in critically ill pediatric patients. Emerging strategies such as physiologically based pharmacokinetic modeling, personalized dosing, and therapeutic drug monitoring offer promising solutions for optimizing drug therapy in children. By synthesizing recent findings from the articles published between 2015 and 2024, this review highlights the importance of advancing pediatric pharmacotherapy through collaborative efforts among clinicians, researchers, and regulatory bodies to ensure safe and effective treatment outcomes.

Keywords: Critical care, Drug development, Formulation, Obesity, Pediatric pharmacotherapy, Pharmacokinetics, Personalized dosing, Therapeutic monitoring, Physiologically based pharmacokinetic models

INTRODUCTION

Pediatric pharmacotherapy is a multifaceted discipline that demands careful attention to age-specific variations in drug response. From neonates to adolescents, physiological differences significantly impact drug pharmacokinetics and pharmacodynamics, necessitating tailored therapeutic approaches. For instance, neonates have immature hepatic enzyme systems, affecting drug metabolism, while adolescents experience hormonal changes that can alter pharmacokinetic profiles. These differences underscore the critical need for age-appropriate drug formulations and dosing strategies to optimize therapeutic outcomes.

The pediatric population also faces unique challenges due to the lack of extensive clinical trials involving children, as ethical and logistical barriers often limit robust data collection. This has led to a reliance on extrapolated adult data for pediatric drug development, which may not always accurately reflect the needs of younger patients. Consequently, advancements in physiologically based pharmacokinetic (PBPK) modeling and personalized medicine are vital to bridge these gaps and improve the safety and efficacy of pediatric pharmacotherapy.

Insights into critical care management

The Society of Critical Care Medicine Clinical Practice Guidelines offer invaluable insights into pain, sedation, and delirium management in critically ill pediatric patients. These evidence-

based guidelines underscore the importance of routine monitoring, protocolized sedation, and non-pharmacological interventions in optimizing patient outcomes.[1-3]

Navigating obesity considerations

Pediatric obesity poses unique challenges in drug dosing and therapeutic efficacy. Despite the significant impact of obesity on pharmacokinetics, evidence-based dosage recommendations for obese pediatric patients remain limited.[4-8] Future research endeavors should prioritize the development of comprehensive guidelines to inform therapeutic decision-making in this vulnerable population.

Understanding pediatric pharmacokinetics

An in-depth understanding of pediatric pharmacokinetics is paramount for safe and effective drug therapy. Anatomical and physiological variances in children significantly influence drug absorption, distribution, metabolism, and excretion.[9-14] Overcoming challenges associated with conducting pharmacokinetic studies in pediatric populations requires innovative approaches, including alternative sampling techniques and population-based modeling.

Addressing formulation challenges

Pediatric drug development encounters formidable hurdles in formulating age-appropriate dosage forms. Regulatory initiatives incentivize pharmaceutical companies to conduct pediatric clinical studies aimed at addressing formulation challenges and ensuring therapeutic equivalence.[6-8] The prioritization of ease of administration, palatability, stability, and therapeutic equivalency in pediatric dosage forms is imperative to enhance treatment adherence and efficacy.[15-19]

Exploring emerging strategies

PBPK modeling emerges as a promising tool for optimizing drug exposure in pediatric populations.[10,15] Personalized dosing strategies, therapeutic drug monitoring, and pharmacogenetic approaches hold immense potential in enhancing treatment precision and therapeutic outcomes.

METHODOLOGY

The methodology involved identifying recent articles (published between 2015 and 2024) from reputable journals and databases. Articles were selected based on relevance to pediatric pharmacotherapy, including pharmacokinetics, pharmacodynamics, drug development, and clinical practice guidelines. Those articles were selected for review, which covered a range of topics from drug dosing in premature infants to therapeutic drug monitoring. The information extracted from each article was synthesized to provide a comprehensive overview of pediatric pharmacotherapy considerations.

RESULTS

The review identified several key considerations in pediatric pharmacotherapy, including:

- Physiological differences affecting drug pharmacokinetics in children
- Challenges in conducting pharmacokinetic studies in pediatric populations
- Formulation considerations for age-appropriate drug delivery
- Impact of obesity on drug pharmacokinetics and dosing
- Therapeutic drug monitoring strategies for optimizing drug therapy
- Considerations for managing drug–drug interactions in hospitalized pediatric patients
- Renal ontogeny and its implications for drug dosing in children.

DISCUSSION

The findings highlight the importance of understanding pediatric pharmacokinetics and pharmacodynamics to ensure safe and effective drug therapy in children of all ages. Age-specific physiological variations, such as renal and hepatic maturation, influence drug absorption, metabolism, and excretion, necessitating tailored dosing guidelines. For example, the ontogeny of renal function significantly affects the clearance of really excreted drugs in neonates and infants, as reported by Ren *et al*.[16] Similarly, hepatic enzyme maturation plays a pivotal role in the metabolism of drugs such as anticonvulsants and antibiotics.

Future research directions include refining pharmacokinetic modeling techniques to account for interindividual variability among pediatric patients.[16] Studies by Rioux and Waters[15] suggest that PBPK models can provide valuable insights into drug behavior across different pediatric age groups. In addition, personalized pharmacotherapy approaches, incorporating pharmacogenetic data, could further optimize treatment outcomes by tailoring therapies to individual genetic profiles.

The discussion also emphasizes the need for collaborative efforts among researchers, clinicians, and regulatory bodies to address the paucity of pediatric-specific data. Initiatives such as the European Paediatric Translational Research Infrastructure aim to foster international cooperation and advance pediatric drug development. Such efforts are critical to ensuring that children have access to safe, effective, and evidence-based pharmacotherapy.

CONCLUSION

Pediatric pharmacotherapy epitomizes a dynamic intersection of science, clinical practice, and patient care. By embracing evidence-based practices, personalized dosing strategies, and collaborative endeavors, the pediatric pharmacotherapy community can navigate existing challenges and harness emerging opportunities to advance the field. Continued collaboration among clinicians, researchers, and regulatory bodies is indispensable in ensuring optimal therapeutic outcomes for pediatric patients.

Ethical approval: Institutional Review Board approval is not required.
Declaration of patient consent: Patient's consent not required as there are no patients in this study.
Financial support and sponsorship: Nil.
Conflicts of interest: There are no conflicts of interest.
Use of artificial intelligence (AI)-assisted technology for manuscript preparation: The authors confirm that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript and no images were manipulated using AI.

REFERENCES

1. Smith HA, Besunder JB, Betters KA, Johnson PN, Srinivasan V, Stormorken A, *et al.* 2022 society of critical care medicine clinical practice guidelines on prevention and management of pain, agitation, neuromuscular blockade, and delirium in critically ill pediatric patients with consideration of the ICU environment and early mobility. Pediatr Crit Care Med 2022;23:e110.
2. Tragiannidis A, Groll AH, Walsh TJ, Roilides E. Antifungal agents and the kidney: Pharmacokinetics, clinical nephrotoxicity, and interactions. Expert Opin Drug Saf 2021;20:1061-74.
3. Anderson BJ, Bagshaw O, Palmer GM, Scott DA, Stokes MA. Pharmacokinetic and pharmacodynamic considerations of general anesthesia in pediatric subjects. Expert Opin Drug Metab Toxicol 2020;16:279-95.
4. Samuels S, Sherbet DM, Alexander M, Burckart GJ, Laughon MM, Barrett JS, *et al.* Obesity considerations in pediatric drug development, 2016–2021. J Clin Pharmacol 2023;63 Suppl 2:S18-24.
5. Tunehag KR, Cohen-Wolkowiez M, Yao Y, Walenga I, Myra BJ, Benjamin DK Jr., *et al.* Food-drug effects and pediatric drug development studies submitted to the US Food and Drug Administration, 2012–2022. J Clin Pharmacol 2024;64:697-703.
6. Pan X, Tracton G, Allman EM, Lim WM, Cohen-Wolkowiez M. Model-informed approaches to support drug development for patients with obesity: A regulatory perspective. J Clin Pharmacol 2023;63 Suppl 2:S65-77.
7. Lavan M, Sigfridson K, Edwards K, Downes N, Gonzalez V. Development of a pediatric mini-tablet formulation for expedited preclinical studies. AAPS PharmSciTech 2021;22:40.
8. Ali AA, York P, Blagden N, Roberts M. Pediatric drug development: Formulation considerations. Drug Dev Ind Pharm 2014;40:1283-99.
9. Batchelor HK, Marriott JF. Paediatric pharmacokinetics: Key considerations. Br J Clin Pharmacol 2015;79:395-404.
10. Lim SY, Pettit RS. Pharmacokinetic considerations in pediatric pharmacotherapy. Am J Health Syst Pharm 2019;76:1472-80.
11. Zimmerman KO, Hornik CP, Greenberg RG, Laughon MM. Neonatal therapeutics: Considerations for dosing. Am J Perinatol 2019;36 Suppl 2:S18-21.
12. Tauzin M, Bourguignon L, Bleyzac N. Pharmacokinetic and pharmacodynamic considerations of cephalosporin use in children. Expert Opin Drug Metab Toxicol 2019;15:869-80.
13. Lang J, Bennett M, Cacabelos R, Zou X. Impact of hepatic CYP3A4 ontogeny functions on drug-drug interaction risk in pediatric physiologically-based pharmacokinetic/pharmacodynamic modeling: Critical literature review and ivabradine case study. Clin Pharmacol Ther 2021;109:1618-30.
14. Van den Anker JN, Allegaert K. Considerations for drug dosing in premature infants. J Clin Pharmacol 2021;61 Suppl 1:S141-51.
15. Rioux N, Waters NJ. Physiologically based pharmacokinetic modeling in pediatric oncology drug development. Drug Metab Dispos 2016;44:934-43.
16. Ren Z, Bremer AA, Pawlyk AC. Drug development research in pregnant and lactating women. Am J Obstet Gynecol 2021;225:33-42.
17. Brunet M, Shipkova M, van Gelder T, Hesselink DA, Budde K, Barten MJ, *et al.* Therapeutic drug monitoring of tacrolimus-personalized therapy: Second consensus report. Ther Drug Monit 2019;41:261-307.
18. Gonzalez D, Sinha J. Pediatric drug-drug interaction evaluation: Drug, patient population, and methodological considerations. J Clin Pharmacol 2021;61 Suppl 1:S175-87.
19. Balyan R, Caudle KE, Hinds DS. Pharmacokinetic and pharmacodynamic considerations in developing a response to the opioid epidemic. Expert Opin Drug Metab Toxicol 2020;16:125-41.

How to cite this article: Khan TB. Advancements and challenges in pediatric pharmacotherapy: A comprehensive review. Glob J Health Sci Res. doi: 10.25259/GJHSR_50_2024